About Aardark Therapeutics
Aardark Therapeutics is a company based in San Diego (United States) founded in 2017. Aardark Therapeutics has raised $138 million across 4 funding rounds from investors including Sorrento Therapeutics, Cantor and Tetragon. The company has 22 employees as of December 31, 2024. Aardark Therapeutics offers products and services including ARD-101. Aardark Therapeutics operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
- Headquarter San Diego, United States
- Employees 22 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aardvark Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$20.59 M (USD)-185.63as on Dec 31, 2024
-
EBITDA
-$22.77 M (USD)-211.14as on Dec 31, 2024
-
Total Equity Funding
$138 M (USD)
in 4 rounds
-
Latest Funding Round
$85 M (USD), Series C
May 01, 2024
-
Investors
Sorrento Therapeutics
& 16 more
-
Employee Count
22
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aardark Therapeutics
Aardark Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AARD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aardark Therapeutics
Aardark Therapeutics offers a comprehensive portfolio of products and services, including ARD-101.
Oral drug activating receptors to suppress hunger for rare diseases
People of Aardark Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Aardark Therapeutics
Aardark Therapeutics has successfully raised a total of $138M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $85 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aardark Therapeutics
Aardark Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Sorrento Therapeutics, Cantor and Tetragon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked | |
|
Investments in healthcare companies are made by SymBiosis.
|
Locked | Locked | Locked | |
|
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources.
|
Locked | Locked | Locked |
Investor details for Aardark Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aardark Therapeutics
Investment portfolio details for Aardark Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aardark Therapeutics
Detailed financials for Aardark Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aardark Therapeutics Comparisons
Peer comparison for Aardark Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aardark Therapeutics
Aardark Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Detailed competitors of Aardark Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aardark Therapeutics
Complete news archive for Aardark Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aardark Therapeutics
Aardark Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Aardark Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Tien Lee is the current CEO of Aardark Therapeutics.
Aardark Therapeutics is a funded company, having raised a total of $138M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Aardark Therapeutics is 22.
Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders. Their lead candidate, ARD-101 is an oral composition that selectively disrupts hunger signaling and regulates energy homeostasis. The candidate helps through increasing metabolic rate, interfering with nutrient absorption, or directly modifying CNS pathways, all of which are related to undesirable off-target effects.
Aardark Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.
Aardark Therapeutics offers ARD-101.
Yes, Aardark Therapeutics is publicly traded on NASDAQ under the ticker symbol AARD.
Aardark Therapeutics has 17 investors. Key investors include Sorrento Therapeutics, Cantor, Tetragon, Decheng Capital, and Cormorant.
The ticker symbol of Aardark Therapeutics is AARD on NASDAQ.